{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:39Z","timestamp":1786119519061,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1097\/mjt.0b013e31815adf85","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T06:48:54Z","timestamp":1279090134000},"page":"e88-e99","source":"Crossref","is-referenced-by-count":3,"title":["Dual Inhibition, Newer Paradigms for Cholesterol Lowering"],"prefix":"10.1097","volume":"17","author":[{"given":"Srikanth","family":"Katragadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210202","first-page":"e85","article-title":"Heart disease and stroke statistics: 2006 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation"},{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/jcem.87.2.8057","article-title":"Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.","volume":"87","author":"Kreisberg","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association; for the Coordinating Committee of the National Cholesterol Education Program. Adult treatment panel III guidelines.","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the NCEP writing group recommendations.","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC; National Heart, Lung, and Blood Institute. AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute.","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"R8-11-20210202","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1520-037X.2007.05512.x","article-title":"High-density lipoprotein cholesterol: a potential therapeutic target for prevention of coronary artery disease.","volume":"10","author":"Chernobelskey","year":"2007","journal-title":"Prev Cardiol"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport.","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"R10-11-20210202","first-page":"1436","article-title":"Apolipoprotein A-I and high-density lipoprotein.","volume":"44","author":"Ballantyne","year":"2004","journal-title":"Am Coll Cardiol"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1172\/JCI11538","article-title":"Tangier disease as a test of the reverse cholesterol transport hypothesis.","volume":"106","author":"Tall","year":"2000","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"R14-11-20210202","first-page":"11698","article-title":"Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism.","volume":"79","author":"McLeod","year":"2004","journal-title":"Am J Clin Nutrition"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.2174\/138161205774580732","article-title":"Direct interaction of dietary lipids carried in chylomicron remnants with cells of the artery wall: implications for atherosclerosis development.","volume":"11","author":"Botham","year":"2005","journal-title":"Curr Pharm Des"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5551\/jat.12.73","article-title":"Remnant lipoproteins and atherogenesis.","volume":"12","author":"Kawakami","year":"2005","journal-title":"J Atheroscler Thromb"},{"key":"R17-11-20210202","first-page":"653","article-title":"Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease.","volume":"11","author":"Groot","year":"1991","journal-title":"Atheroscler Thromb"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","article-title":"The evolving role of statins in the management of atherosclerosis.","volume":"35","author":"Vaughan","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00041433-199912000-00011","article-title":"Fibrates, dyslipoproteinaemia and cardiovascular disease.","volume":"10","author":"Watts","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"735","DOI":"10.4065\/78.6.735","article-title":"Niacin as a component of combination therapy for dyslipidemia.","volume":"78","author":"Miller","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1-like 1 protein is critical for intestinal cholesterol absorption.","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Treating to New Targets investigators.","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"R23-11-20210202","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.","volume":"294","author":"Pederson","year":"2005","journal-title":"JAMA"},{"key":"R25-11-20210202","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.","volume":"149","author":"Ballantyne","year":"2005","journal-title":"J Am Heart J"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clinthera.2005.02.011","article-title":"Ezetimibe Study Group. Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.","volume":"27","author":"Masana","year":"2005","journal-title":"Clin Ther"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4065\/79.5.620","article-title":"Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.","volume":"79","author":"Goldberg","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On To Statin For Effectiveness (EASE) Trial.","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R32-11-20210202","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-6143.2005.01132.x","article-title":"Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.","volume":"6","author":"Kohnle","year":"2006","journal-title":"Am J Transplant"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.","volume":"47","author":"Landray","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R35-11-20210202","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"R36-11-20210202","first-page":"772","article-title":"Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia.","volume":"98","author":"Rodney","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1089\/jwh.2004.13.1101","article-title":"Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.","volume":"13","author":"Bennett","year":"2004","journal-title":"J Womens Health (Larchmt)"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2165\/00002512-200421150-00005","article-title":"Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia.","volume":"21","year":"2004","journal-title":"Drugs Aging"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00228-006-0238-4","article-title":"The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.","volume":"63","author":"Efrati","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R43-11-20210202","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin [the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation (ADVOCATE)].","volume":"91","year":"2003","journal-title":"Am J Cardiol"},{"key":"R45-11-20210202","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00002018-200629080-00007","article-title":"Effect of ezetimibe and\/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.","volume":"29","author":"Berthold","year":"2006","journal-title":"Drug Safety"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201007000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:27:17Z","timestamp":1786040837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201007000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31815adf85","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}